LG Life Sciences

Quick facts

Marketed products

• Enbrel · Oncology
• IVF-M HP Inj. · Reproductive Medicine / Fertility
  IVF-M HP is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing assisted reproductive therapy.
• Kytril inj.+Kytril tab. · Oncology, Anesthesia
  Granisetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.
• Menopur® Inj. · Reproductive Medicine / Fertility
  Menopur is a purified preparation of human menopausal gonadotropins (hMG) containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and hormone production in women undergoing fertility treatment.
• Sancuso patch · Oncology
  Sancuso is a granisetron transdermal patch that blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
• Zofran inj.+Zofran tab. · Oncology, Gastroenterology, Anesthesia
  Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Phase 3 pipeline

• Eutravac · Other
• Eutropin · Other
• Gemigliptin and/or Rosuvastatin · Diabetes and Cardiovascular
  Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol.
• Gemigliptin/Glimepiride combination · Diabetes
  Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and insulin secretion, while glimepiride stimulates pancreatic beta cells to release insulin directly.
• Growth hormone - LB03002
• Hiberix™ Vaccine · Immunology / Infectious Disease
  Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.
• Hyruan Plus · Orthopedics / Rheumatology
  Hyruan Plus is a viscoelastic hyaluronic acid-based injection that provides lubrication and cushioning to damaged joints.
• LBAL
  LBAL is a therapeutic agent in development by LG Life Sciences, currently in phase 3 clinical trials.
• LBEC0101
  LBEC0101 is a therapeutic candidate in phase 3 development by LG Life Sciences with an undisclosed or proprietary mechanism of action.
• LBSA0103 · Diabetes
  LBSA0103 is a small molecule that targets the SGLT2 receptor.
• LBVH0101 (Hib vaccine) · Immunology
  LBVH0101 is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates the immune system to produce antibodies against Hib polysaccharide capsule.
• Placebo(Gemigliptin) · Diabetes
  Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes.
• Placebo group(once daily)
  A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.
• Placebo to Linagliptin · Diabetes
  Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion.

Phase 2 pipeline

• human growth hormone self-injection
• LC28-0126 Dose A
• LC28-0126 Dose B
• LC28-0126 Dose C
• LD02GIFRO
• Lercanidipine or Valsartan
• Levacalm · Other

Phase 1 pipeline

• [14C]-LC15-0444
• Apetrol ES
• BEPO-A
• Gemigliptin and Glimepiride
• gemigliptin and rosuvastatin
• gemigliptin only
• LB80380 free base
• LB80380 maleate salt
• LC15-0444
• LC15-0444, Pioglitazone
• LC23-1306
• REPO-A
• rosuvastatin only

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• LG Life Sciences portfolio CI brief
• LG Life Sciences pipeline updates RSS